Antiverse Secures $9.3M to Scale AI-Powered Antibody Discovery
▼ Summary
– Antiverse, a UK biotech company, has raised $9.3 million in Series A funding to expand its AI platform and advance its therapeutic antibody programs.
– The company uses machine learning to design antibodies for challenging drug targets, such as GPCRs, that are difficult to address with traditional methods.
– The new funding will be used to scale its AI technology, progress internal drug programs, and expand collaborations with pharmaceutical partners.
– This financing reflects the growing integration of AI into mainstream drug discovery, particularly for historically difficult biological targets.
– A key challenge for Antiverse will be translating its computational designs into validated therapeutic candidates that succeed in preclinical testing.
A biotechnology firm based in Cardiff has secured a significant investment to expand its work in artificial intelligence-driven drug discovery. Antiverse has closed a $9.3 million Series A financing round, with the capital dedicated to scaling its computational platform and advancing its internal therapeutic programs toward in vivo studies. The funding was spearheaded by Soulmates Ventures, with additional investment from Innovation Investment Capital, DOMiNO Ventures, and existing supporters such as DBW, Kadmos Capital, and & Biotech Fund.
The company specializes in applying machine learning to the early stages of biologic drug development, with a particular focus on therapeutic antibodies. Its platform is engineered to model how antibodies interact with antigens, generating tailored candidate sequences. This approach is especially valuable for tackling challenging protein families like G-protein coupled receptors (GPCRs) and ion channels, which have traditionally been difficult to address using standard laboratory methods. The AI-generated designs undergo rigorous laboratory validation to confirm their binding capability, specificity, and overall therapeutic potential before moving forward.
This Series A round represents Antiverse’s first major institutional growth financing, building upon earlier seed equity and venture rounds. Prior investments have brought the company’s total funding to over $20 million. The new capital will be used to enhance the AI platform, progress internal drug programs, and broaden its collaborative discovery services for pharmaceutical partners. Its target clients are primarily pharmaceutical and biotech companies looking to speed up the early discovery phases, especially for targets that have resisted conventional biologic approaches.
The market for AI in drug discovery has evolved considerably, moving from experimental projects to a mainstream component of research and development. Many startups and established labs now integrate machine learning to hasten target identification and optimize lead compounds. Antiverse’s specific concentration on antibodies for difficult targets highlights ongoing inefficiencies in traditional discovery that AI tools aim to solve. While several European companies operate in generative design and biotechnology, few have secured Series A investments of this size that are so sharply focused on biologics.
In a sector where many ventures struggle to move beyond initial proof-of-concept stages, this financing provides Antiverse with a crucial runway. It allows the company to strengthen its technological edge and grow its role as an external discovery partner for complex targets. The investment also helps solidify Cardiff and the wider UK biotech cluster as a notable hub for innovation in AI-augmented drug discovery. The primary challenge ahead involves translating computational predictions into tangible therapeutic candidates that can withstand the demands of preclinical testing and regulatory scrutiny. The company’s future growth will likely be shaped by its success in attracting and maintaining partnerships within the pharmaceutical and biotechnology industries.
(Source: The Next Web)
